Beyond Rebates: PhRMA Wants HHS To ‘De-Link’ Supply Chain Compensation From List Price
Focus should not be limited to rebates in Medicare Part D, manufacturers advise in comments on HHS drug pricing blueprint. Pharmacy benefit managers raise anti-trust issues with shift to upfront discounts.
You may also be interested in...
Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.
Congressional Budget Office agrees with the Office of Management and Budget that passing through negotiated rebates to Medicare Part D beneficiaries at the point-of-sale would significantly increase Medicare spending.